Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Chubb
Baxter
Healthtrust
Fish and Richardson
Daiichi Sankyo
Boehringer Ingelheim
Fuji

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,006,224

« Back to Dashboard

Which drugs does patent 9,006,224 protect, and when does it expire?

Patent 9,006,224 protects AFINITOR and is included in one NDA.

This patent has forty-one patent family members in twenty-three countries.
Summary for Patent: 9,006,224
Title:Neuroendocrine tumor treatment
Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
Inventor(s): Marks; Peter Wayne (Woodbridge, CT), Lebwohl; David (Madison, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:12/094,173
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,006,224
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,006,224

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ➤ Try a Free Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ➤ Try a Free Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ➤ Try a Free Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,006,224

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0523658.3Nov 21, 2005
United Kingdom0601082.1Jan 19, 2006
United Kingdom0602747.8Feb 10, 2006
United Kingdom0607942.0Apr 21, 2006
PCT Information
PCT FiledNovember 20, 2006PCT Application Number:PCT/EP2006/068656
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/057457

International Family Members for US Patent 9,006,224

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101360496 ➤ Try a Free Trial
China 103446138 ➤ Try a Free Trial
Cyprus 1115299 ➤ Try a Free Trial
Denmark 2275103 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
McKinsey
Accenture
Healthtrust
Cipla
Moodys
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.